Business
The partnership will allow BMS to advance a T cell–based therapy that is only activated once in the vicinity of a tumor.
FEATURED STORIES
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
GlaxoSmithKline has declined all three of Unilever PLC’s offers to acquire its Consumer Healthcare business, saying that the proposal undervalued the division’s present and further worth.
Beatrice Mintz, the research legend passed away at the age of 100. Her contribution to the field is unforgettable. ere’s more about her and the research.
Emergent BioSolutions, Vir Biotechnology and Thermo Fisher, come into 2022 with reports of new opportunities, new vaccines, and partnership expansions.
Relief said that NRx’s claims that their partnership has been canceled were untrue and that it believes their collaboration involving aviptadil remains active and in full force.
Today, Noubar Afeyan, founder of Flagship Pioneering, published the platform development company’s 2022 Annual Letter, and in it, outlined what he sees as the four top forces shaping the future of biotech.
Affini-T Therapeutics unveiled its mission to target oncogenic driver mutations to deliver transformative therapies intended to cure patients.
Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look.
Former Food and Drug Commissioner Robert Califf is one step closer to returning to his old office after the Senate Health, Education, Labor and Pensions Committee advanced his nomination.
The company’s vision for the next few years includes annual revenue of $5 billion by 2025 and the approval of at least five novel products by the end of the decade.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.